← All trials
NCT03636659
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 2, 2018
- Primary completion
- Mar 31, 2019
- Completion date
- Mar 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 140
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Aurobindo PharmaLead sponsor
- Aurobindo PharmaStudy chair
- AXIS Clinicals LimitedStudy director
- AXIS Clinicals LimitedCollaborator
- International Center for Diarrheal Disease ResearchOverall official - principal investigator
- Kala-azar Medical Research CentreOverall official - principal investigator
- Rajendra Memorial Research Institute of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.